Genomic Tests Firm Exagen Buying Cypress’ Dx Biz | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exagen Diagnostics has agreed to buy the diagnostics business of Cypress Bioscience for up to $8 million in upfront and milestone payments.

Under the terms of the agreement announced Friday after the close of the market, Exagen will pay $4 million upfront, split into two separate payments 24 months apart, Cypress said in a statement. Exagen will also make milestone payments totaling up to $4 million and pay a 10 percent royalty to Cypress on defined product sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.